{"title":"阿斯利康在研发受挫后签署两项协议加强产品线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I1.1652","DOIUrl":null,"url":null,"abstract":"After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline. In a deal potentially worth more than US$140 M, AstraZeneca has licensed rights from Hutchison MediPharma to co-develop and commercialise volitinib, a preclinical c-Met receptor tyrosine kinase inhibitor being developed for cancer. The company has also obtained an option to acquire the type 2 diabetes assets of Astellas Pharma’s Prosidion subsidiary, Phase II PSN821 and preclinical-stage PSN842.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"108 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I1.1652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline. In a deal potentially worth more than US$140 M, AstraZeneca has licensed rights from Hutchison MediPharma to co-develop and commercialise volitinib, a preclinical c-Met receptor tyrosine kinase inhibitor being developed for cancer. The company has also obtained an option to acquire the type 2 diabetes assets of Astellas Pharma’s Prosidion subsidiary, Phase II PSN821 and preclinical-stage PSN842.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"108 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I1.1652\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I1.1652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks
After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline. In a deal potentially worth more than US$140 M, AstraZeneca has licensed rights from Hutchison MediPharma to co-develop and commercialise volitinib, a preclinical c-Met receptor tyrosine kinase inhibitor being developed for cancer. The company has also obtained an option to acquire the type 2 diabetes assets of Astellas Pharma’s Prosidion subsidiary, Phase II PSN821 and preclinical-stage PSN842.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
